PMID- 33159376
OWN - NLM
STAT- MEDLINE
DCOM- 20210301
LR  - 20221005
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Print)
IS  - 1347-9032 (Linking)
VI  - 112
IP  - 1
DP  - 2021 Jan
TI  - Expression of human leukocyte antigen class I and beta2-microglobulin in colorectal 
      cancer and its prognostic impact.
PG  - 91-100
LID - 10.1111/cas.14723 [doi]
AB  - Downregulation of human leukocyte antigen (HLA) class I has been postulated to be 
      a mechanism of adaptive immune escape in various tumors, especially 
      microsatellite instability-high (MSI-H) colorectal cancer (CRC). In this study, 
      we aimed to investigate HLA class I and beta2-microglobulin (beta2M) expression in 
      MSI-H and microsatellite-stable (MSS) CRCs and determine its prognostic impact. 
      The representative areas from the tumor center (TC) and tumor periphery (TP) from 
      300 CRCs, including 161 MSI-H and 139 MSS cases, were selected to construct a 
      tissue microarray. Immunohistochemistry (IHC) for HLA A/B/C, beta2M, CD3, and CD8 
      was performed. Reduced HLA A/B/C expression was detected in 113 (70.2%) MSI-H and 
      54 (38.8%) MSS cases, while reduced beta2M expression was observed in 69 (42.9%) 
      MSI-H and 17 (12.2%) MSS cases. Although reduced beta2M expression was associated 
      with higher pathological tumor (pT) stage in MSI-H CRC with borderline 
      significance, no association was found between HLA A/B/C and beta2M expression and 
      survival. Interestingly, reduced HLA A/B/C expression in MSS was associated with 
      higher stage, and reduced HLA A/B/C and beta2M expression was an independent 
      prognostic factor in multivariate analysis. In conclusion, reduced HLA A/B/C and 
      beta2M expression was frequently observed in immunotherapy-naive MSI-H CRC, 
      suggesting the possibility of primary resistance to immune checkpoint inhibitor. 
      Interestingly, downregulation of HLA A/B/C and beta2M was associated with poor 
      prognosis in MSS cancers. Overall, IHC for HLA A/B/C and beta2M might be a feasible 
      predictive or prognostic tool in CRC.
CI  - (c) 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd 
      on behalf of Japanese Cancer Association.
FAU - Na, Hee Young
AU  - Na HY
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam-si, Korea.
FAU - Park, Yujun
AU  - Park Y
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam-si, Korea.
FAU - Nam, Soo Kyung
AU  - Nam SK
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam-si, Korea.
FAU - Lee, Kyu Sang
AU  - Lee KS
AD  - Department of Pathology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam-si, Korea.
FAU - Oh, Heung-Kwon
AU  - Oh HK
AD  - Department of Surgery, Seoul National University Bundang Hospital, Seoul National 
      University College of Medicine, Seongnam-si, Korea.
FAU - Kim, Duck-Woo
AU  - Kim DW
AD  - Department of Surgery, Seoul National University Bundang Hospital, Seoul National 
      University College of Medicine, Seongnam-si, Korea.
FAU - Kang, Sung-Bum
AU  - Kang SB
AD  - Department of Surgery, Seoul National University Bundang Hospital, Seoul National 
      University College of Medicine, Seongnam-si, Korea.
FAU - Kim, Woo Ho
AU  - Kim WH
AD  - Department of Pathology, Seoul National University Hospital, Seoul National 
      University College of Medicine, Seoul, Korea.
FAU - Lee, Hye Seung
AU  - Lee HS
AUID- ORCID: 0000-0002-1667-7986
AD  - Department of Pathology, Seoul National University Hospital, Seoul National 
      University College of Medicine, Seoul, Korea.
LA  - eng
GR  - 14-2017-002/SNUBH Research Fund/
PT  - Journal Article
DEP - 20201128
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (beta 2-Microglobulin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/*genetics/*pathology
MH  - Down-Regulation/genetics
MH  - Female
MH  - Histocompatibility Antigens Class I/*genetics
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - Male
MH  - Microsatellite Instability
MH  - Microsatellite Repeats/genetics
MH  - Middle Aged
MH  - Prognosis
MH  - Young Adult
MH  - beta 2-Microglobulin/*genetics
PMC - PMC7780028
OTO - NOTNLM
OT  - colorectal cancer
OT  - human leukocyte antigen class I
OT  - immunohistochemistry
OT  - microsatellite instability
OT  - beta2-microglobulin
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/11/08 06:00
MHDA- 2021/03/02 06:00
PMCR- 2021/01/01
CRDT- 2020/11/07 05:35
PHST- 2020/07/22 00:00 [received]
PHST- 2020/10/10 00:00 [revised]
PHST- 2020/11/04 00:00 [accepted]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2021/03/02 06:00 [medline]
PHST- 2020/11/07 05:35 [entrez]
PHST- 2021/01/01 00:00 [pmc-release]
AID - CAS14723 [pii]
AID - 10.1111/cas.14723 [doi]
PST - ppublish
SO  - Cancer Sci. 2021 Jan;112(1):91-100. doi: 10.1111/cas.14723. Epub 2020 Nov 28.